Amgen Inc. $AMGN Stock: Profund Advisors LLC Reduces Position

Profund Advisors LLC cut its position in Amgen Inc. (NASDAQ:AMGN) by 2.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,116 shares of the medical research company’s stock after selling 1,204 shares during the quarter. Amgen comprises 0.6% of Profund Advisors LLC’s investment portfolio, making the stock its 26th biggest position. Profund Advisors LLC’s holdings in Amgen were worth $21,124,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. State Street Corp increased its holdings in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after purchasing an additional 605,928 shares during the period. Bank of America Corp DE bought a new stake in shares of Amgen during the second quarter valued at approximately $1,831,903,000. Finally, Amundi grew its holdings in shares of Amgen by 15.2% in the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after purchasing an additional 512,883 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last quarter. 0.85% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of Amgen stock opened at $466.01 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm’s 50-day moving average price is $419.96 and its two-hundred day moving average price is $374.79. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $475.65. The stock has a market capitalization of $251.94 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 3.41 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period last year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts predict that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s payout ratio is currently 62.65%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. UBS Group lifted their price target on Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and reduced their price target for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. Piper Sandler boosted their target price on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Truist Financial raised their price objective on shares of Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a research note on Wednesday, October 7th. Finally, Morgan Stanley dropped their price objective on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $389.71.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.